We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalABMD - Replacement Heart System

Previous 10 Next 10 
To: High-Tech East who wrote (110)4/14/2003 8:28:42 PM
From: fp_scientist
   of 147
Looks like going to zero to me ...

Did you ever consider THOR as an alternative investment to diversify?


Share RecommendKeepReplyMark as Last Read

To: High-Tech East who wrote (110)6/6/2003 12:13:45 PM
From: Lynn
   of 147
Any comments about where ABMD is headed now, Ken?


Share RecommendKeepReplyMark as Last Read

From: Lynn3/8/2018 6:34:59 PM
   of 147
Why Abiomed Soared 14.1% In February

Brian Feroldi, The Motley Fool,
Motley FoolMarch 8, 2018

What happened In response to pumping out record quarterly results and sharing a slew of upbeat news announcements with investors, shares of Abiomed (NASDAQ: ABMD), a medical device maker focused on heart recovery, jumped 14.1% in February according to data from S&P Global Market Intelligence.

So whatAbiomed got off to a fast start in February after it reported strong fiscal third-quarter results:

  • Revenue grew 34% to $154 million.
  • Adjusted net income more than doubled to $32.2 million.
  • Adjusted earnings per share of $0.70 were far higher than the $0.51 that Wall Street had expected.
  • If that wasn't exciting enough, the company also shared two positive regulatory updates with investors later in the month, including:

  • Winning FDA approval for a label expansion claim for its Impella heart pumps to treat heart failure associated with cardiomyopathy leading to cardiogenic shock.
  • Gaining FDA approval for a label expansion claim for certain Impella heart pumps to be used during elective and urgent high risk percutaneous coronary intervention (PCI) procedures.
  • Given the upbeat financial results and label expansion wins, it isn't hard to figure out why Abiomed's shares remain on fire.

    A surgeon in the foreground with an operation happening in background.
    Image source: Getty Images.

    Now whatBetween label expansion claims, product innovations, and international expansion, there are plenty of reasons for investors to believe that Abiomed's days of hyper growth are here to stay. While the company's stock cannot be called cheap right now -- shares are currently trading for more than 22 times sales and 85 times forward earnings -- I still think the long-term potential of this business is so great that the company can continue to put up market-beating results.

    Share RecommendKeepReplyMark as Last Read

    From: Lynn3/8/2018 6:39:57 PM
       of 147
    Abiomed to pay $3.1 mln to settle case over lavish doctor meals

    ReutersMarch 8, 2018

    (Adds comment from Abiomed, further details from lawsuit)

    By Nate Raymond

    BOSTON, March 8 (Reuters) - Abiomed Inc has agreed to pay $3.1 million to resolve a U.S. probe into allegations that it sought to get doctors to use a line of heart pumps it produced by buying them lavish meals at some of the most expensive restaurants in the United States.

    The civil settlement was announced on Thursday by U.S. Attorney Andrew Lelling in Massachusetts and resolves allegations first raised in a whistleblower lawsuit filed by a former Abiomed employee.

    The government alleged that Danvers, Massachusetts-based Abiomed from 2012 to 2015 sought to get physicians to use its Impella line of heart pumps by paying for their meals at expensive restaurants, according to the settlement agreement.

    The restaurants included Eleven Madison Park in New York, Nobu in Los Angeles, Spago in Beverly Hills, California, and Menton in Boston, Lelling's office said.

    Abiomed in a filing with the U.S. Securities and Exchange Commission said it did not admit liability in settling.

    Abiomed paid for alcohol at times in amounts inconsistent with legitimate scientific discussion and covered meals the physicians' spouses attended, the government alleged.

    Numerous meals cost more than Abiomed's own $150 per person guideline and in one instance cost over $450 per person, the settlement agreement said. In some instances the number of people at a dinner was misrepresented and in other cases attendees were listed with generic names, such as "Mike Anesthesia," the agreement said.

    The government contended the meals led to the submission of false claims for payment for Impella heart pumps that cost more than $20,000 each by Medicare, the federal health care program for the elderly and disabled.

    "We expect today's settlement with Abiomed to serve as a warning to medical device manufacturers who try to improperly influence the treatment decisions of physicians," Lelling said in a statement.

    Abiomed in its SEC filing said the probe revealed that less than 2 percent of the meals it paid for exceeded its internal guidelines.

    The deal stemmed from a lawsuit filed by a former Abiomed employee, Max Bennett, under the False Claims Act, which allows whistleblowers to sue companies on the government's behalf to recover taxpayer money paid out based on fraudulent claims.

    If successful, whistleblowers receive a percentage of the recovery. The settlement agreement said Bennett will receive $542,500. Abiomed said it will also pay $150,000 to Bennett to cover his attorneys' fees and costs.

    Rory Delaney, a lawyer for Bennett, said he was pleased by the settlement. The deal does not resolve claims in Bennett's lawsuit that Abiomed terminated him in 2012 in retaliation for complaining about improper conduct by the company.

    The case is U.S. ex rel. Bennett v. Abiomed Inc, U.S. District Court, District of Massachusetts, No. 13-12277. (Reporting by Nate Raymond in Boston Editing by Susan Thomas and Leslie Adler)

    Share RecommendKeepReplyMark as Last Read

    From: Lynn4/4/2018 4:08:49 PM
       of 147
    Abiomed Receives FDA Approval for Impella CP® with SmartAssist™ and Optical Sensor

    Share RecommendKeepReplyMark as Last Read

    From: Lynn4/6/2018 3:41:40 PM
       of 147
    ABMD is one of the top 10 in which at least $100 million was invested as new buys by mutual funds:

    New Buys By Best Mutual Funds: From Adobe To Zebra, Who Makes The List?

    Share RecommendKeepReplyMark as Last Read

    From: Lynn4/13/2018 2:50:41 PM
       of 147
    DANVERS, Mass., April 13, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. ( NASDAQ:ABMD) announced that on Thursday, May 3, 2018, the Company will release financial results for the fourth quarter of fiscal 2018. The Company will host a conference call to discuss the results on Thursday, May 3, 2018, at 8:00 a.m. EDT. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Vice President and Chief Financial Officer, will host the conference call.

    To listen to the call live, please tune into the webcast via or dial (855) 212-2361; the international number is (678) 809-1538. A replay of this conference call will be available beginning at 11 a.m. ET May 3, 2018 through 11:00 a.m. ET on May 10, 2018. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 448 8806. [snip to end]

    Share RecommendKeepReplyMark as Last Read

    From: Lynn5/9/2018 6:13:27 PM
    1 Recommendation   of 147
    Abiomed Climbs to Record After Fiscal Q4 EPS, Rervenue Beat Analyst Estimates 12:26 PM ET, 05/03/2018 - MT Newswires12:26 PM EDT, 05/03/2018 (MT Newswires) -- Abiomed (ABMD) shares rose 11% to a record after reporting fiscal Q4 EPS of $0.80 compared with $0.33 a year earlier, beating the $0.66 average estimate of analysts in a Capital IQ poll.

    The new 52-week range is $123.60 to $338.69.

    Revenue was $174.4 million, an increase of 40% from $124.7 million a year earlier. That exceeded the $164.3 million analyst consensus.

    The company sees total revenue in the 2019 fiscal year to be in the range of $740 million to $770 million, an increase of 25% to 30% over the previous fiscal year. It sees GAAP operating margin in the range of 28% to 30%.

    Closing price: 358.16 Change +10.78 (+3.1%)

    Share RecommendKeepReplyMark as Last Read

    From: Lynn5/29/2018 2:09:05 PM
       of 147
    ABIOMED Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    Share RecommendKeepReplyMark as Last Read

    From: Lynn6/2/2018 10:04:37 PM
    1 Recommendation   of 147
    Abiomed's Shares Doubled. What Happens Next? The size of this medical device company's market might surprise you.

    Motley Fool Staff

    Jun 1, 2018 at 9:00AM

    Open-heart surgery in patients that have suffered major cardiovascular events is risky, but it could be getting less so thanks to temporary heart pumps sold by Abiomed ( NASDAQ:ABMD), a $17 billion market-cap medical devices company. Is Abiomed a stock worth including in your portfolio?

    In this clip from Industry Focus: Healthcare, analyst Kristine Harjes and Motley Fool contributor Todd Campbell discuss why Abiomed's shares have doubled this year and what investors should know about this company's market opportunity.

    A full transcript follows the video recorded on 30 May 2018 [which I have not included--click the URL at the bottom to watch the video].

    Kristine Harjes: Today, we're going to talk about Abiomed, which is a $17 billion market cap company whose stock has doubled since just January of this year. Both of these companies, Loxo Oncology in the front half of the show, and now Abiomed, have been very, very high performers, but they're both kind of under the radar.

    Abiomed's flagship product line is the Impella heart pump, which is the world's smallest heart pump. Revenue has been growing very swiftly with seemingly no end in sight. Todd, what's your take on Abiomed?

    Todd Campbell: I'm so excited to be talking about this stock. It's kind of funny, right, when you think about it. We oftentimes tend to expect the biggest returns coming from the biopharma area, not from the medical device area. When you see that return year-to-date, it's like, what?! [laughs] Double my money in a few months in this company? Especially for a company as big as this, right? $17 billion market cap! So, you have to ask yourself, what's the excitement here? What's the reason for excitement at Abiomed? And, what's the potential for this company to continue to grow and deliver for investors?

    I think that you did a great job setting the stage here to understand that what they're doing is, through medical devices, they're attacking a very, very big need for devices that can help relieve the stress that gets put on the heart following a heart attack. If you're able to relieve the heart from that stress of pumping on its own, either prior to or during surgery, or in the hours and potentially the days following that surgery, then you can get better outcomes. You can have less of a risk of complications, less of a risk of a readmittance back to the hospital after they've been sent home, and less time overall spent within the hospital, which theoretically can save payers some money there, too.

    So, really, what we're talking about is the Impella heart pumps. Those are used temporarily from hours to a few days. They're used in patients who are at a critical risk -- they've had a heart attack and they're also in shock.

    Harjes: Yeah, absolutely. This is a very, very large market. Heart disease, as many of our listeners will know, is the leading cause of death in the United States. It kills 875,000 people per year. It costs our healthcare system $555 billion, which is estimated to grow to $1.1 trillion annually by 2035. In that same year, 2035, it's estimated that 45% of the United States population will have heart disease, which is just a frightening and insane statistic.

    Abiomed is estimating that about 221,000 U.S. patients per year would benefit from procedures using their Impella product. Despite seeing double-digit growth for revenue for quite a while, they still have a pretty long runway. They're just getting started. They don't seem to have any substantial competitors. They have that first-mover advantage. It looks like it could be early days for this company.

    Campbell: Fiscal year 2017, their sales grew 35% to $445 million. In fiscal year 2018, their sales grew, again, by 33%, to $594 million. I think what got people really excited was the fact that that was better than the guidance. The guidance was for 31% growth, $582 million.

    The other thing that investors should know is that this has been a profitable company since 2012. They're making money. They had $90 million in operating income in fiscal 2017, and then, that jumped in fiscal 2018, just finished up, to $157 million. So, up 74%. Your operating income grew at a much faster rate than your revenue growth, which suggests to me that as these devices are getting used more frequently, they're able to leverage their fixed costs and really accelerate their profitability for investors. Maybe that's one of the reasons that the company is debt free and its cash stockpile has been growing for three consecutive years.

    Harjes: Yeah. The stats that I mentioned were U.S. stats, but they're not even just based in the United States. They're also in Europe, they have approvals there. They launched in Japan in September. They have a presence in Germany. And even though expansion is kind of slow -- and management routinely reminds investors that it has to be slow in order to ensure good outcomes, because you need to be trained to use these pumps, it's not something that you can just drop off and go away -- they have the entire world out there that they're just starting to reach. And when you think about the demographic trends in general across the entire globe of an aging population, I've said it so many times already just in this one segment, but they really do seem like they have a huge runway ahead of them.

    Campbell: Well, just to put that into context, in the fiscal fourth quarter, the one that just wrapped up, their overseas sales, their ex-U.S. sales, were only $22 million. So, a very small proportion of their total sales is coming from the international markets right now. And, by the way, that was up 107% year over year, and it was really tied to one country: Germany. So, as Japan starts to accelerate, as other countries start to get more interested in the opportunity to use Impella, I think that, yeah, you could see sales grow substantially. The company, Kristine, estimates this is a $5 billion market opportunity, and they say that they're only about 9% penetrated into it.

    Harjes: Yep. And the other thing that's important to realize about the business model is that there's recurring revenue. Their hospital reorder rate stands at over 90%. So, it's sticky. Once you're trained on using these, you're probably not going to move to a competitor. I saw on the Premium side of things in our Supernova service, an analyst compared this company to Intuitive Surgical, which is the robotic surgery giant. She pointed out that there were similarities in the business model, where you have that recurring revenue, there's a product that will become the standard of care, there's a long growth runway, and really solid financials. I like that comparison a lot.

    I think one more thing to add to the list of why these two companies are fairly similar is a nosebleed valuation. This company is definitely not cheap, they're trading at about 30X the last 12 months of sales. Their P/E is several hundred, and that's TTM. It's not even that much better when you look on a forward basis. But, like you said, they have a very strong balance sheet. They've been profitable since fiscal 2012. So, I see a lot of similarity with Intuitive.

    Campbell: Yeah. Value investors are not going to be tucking this in a portfolio, similar to what we were talking about last week on the diabetes show. These things are richly valued. But, that's not necessarily a reason to not have a stock like this in your portfolio. You need to take that valuation in the context of where the company's sales could be in five or ten years. You have to take that longer-term look and say, if they're only 9% penetrated into this massive market now, can they grow into that valuation? I'll let someone smarter than me make the answer to that. But, I'm very, very excited by the opportunity to really improve a lot of people's lives. This is a medical device that can save lives. That makes the potential for it to be a must-use device in hospitals, not a nice-to-have device.

    Kristine Harjes has no position in any of the stocks mentioned. Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. Motley Fool owns shares of and recommends Abiomed and ISRG. The Motley Fool has a disclosure policy

    Share RecommendKeepReplyMark as Last Read
    Previous 10 Next 10